Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Tokyo Stock Exchange  >  Astellas Pharma Inc.    4503   JP3942400007

ASTELLAS PHARMA INC.

(4503)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
  • The company has solid fundamentals for a short-term investment strategy.
Strengths
  • Share prices are approaching a strong support area in daily data, which offers good timing for investors.
  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • With a P/E ratio at 13.29 for the current year and 11.69 for next year, earnings multiples are highly attractive compared with competitors.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • The technical configuration over the long term remains negative on the weekly chart below the resistance level at 1713.5 JPY
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ASTELLAS PHARMA INC.-21.34%26 300
JOHNSON & JOHNSON-1.30%382 350
ROCHE HOLDING AG-5.29%280 884
PFIZER INC.-3.22%212 162
MERCK & CO., INC.-13.32%201 909
NOVARTIS AG-16.78%185 999
NOVO NORDISK A/S15.16%164 690
ABBVIE INC.-5.22%148 846
ASTRAZENECA PLC6.18%135 994
BRISTOL-MYERS SQUIBB COMPAN..-7.04%135 529
AMGEN INC.-6.71%133 046
ELI LILLY AND COMPANY7.81%129 063
SANOFI-7.59%123 347
GLAXOSMITHKLINE PLC-24.41%87 270
JIANGSU HENGRUI MEDICINE CO..22.28%69 658
CHUGAI PHARMACEUTICAL CO., ..24.02%67 163
More Results
Financials
Sales 2021 1 274 B 12 154 M 12 154 M
Net income 2021 204 B 1 948 M 1 948 M
Net cash 2021 450 B 4 291 M 4 291 M
P/E ratio 2021 13,3x
Yield 2021 2,87%
Capitalization 2 732 B 26 055 M 26 067 M
EV / Sales 2021 1,79x
EV / Sales 2022 1,60x
Nbr of Employees 15 883
Free-Float 99,2%
Upcoming event on ASTELLAS PHARMA INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes